---
import BaseLayout from '../../layouts/BaseLayout.astro';
import MedicalDisclaimer from '../../components/MedicalDisclaimer.astro';
---

<BaseLayout 
  title="Triple Agonist Peptides: What They Are & Why They Work Better (2026)"
  description="Triple agonist peptides like retatrutide target 3 receptors (GLP-1/GIP/Glucagon) for superior weight loss vs dual or single agonists. Learn how they work."
>
  <style>
    .hero { background: linear-gradient(135deg, #ec4899 0%, #db2777 100%); color: white; padding: 80px 24px 60px; text-align: center; }
    .hero h1 { font-size: clamp(2rem, 5vw, 2.8rem); font-weight: 700; margin-bottom: 16px; line-height: 1.2; }
    .content { max-width: 900px; margin: 0 auto; padding: 60px 24px 120px; }
    .content h2 { font-size: 2rem; font-weight: 700; margin: 48px 0 16px; }
    .content p { font-size: 1.05rem; line-height: 1.7; color: #4b5563; margin-bottom: 20px; }
    .content ul { margin: 20px 0; padding-left: 24px; }
    .content li { font-size: 1.05rem; line-height: 1.7; color: #4b5563; margin-bottom: 12px; }
  </style>

  <div class="hero">
    <h1>Triple Agonist Peptides: The Future of Weight Loss</h1>
    <p>Why targeting 3 hormone receptors delivers better results than single or dual agonists.</p>
  </div>

  <div class="content">
    <h2>What Are Triple Agonist Peptides?</h2>
    <p>Triple agonist peptides activate <strong>three hormone receptors simultaneously</strong>:</p>
    <ol>
      <li><strong>GLP-1 (Glucagon-Like Peptide-1):</strong> Reduces appetite, slows digestion</li>
      <li><strong>GIP (Glucose-Dependent Insulinotropic Polypeptide):</strong> Improves insulin response, fat metabolism</li>
      <li><strong>Glucagon:</strong> Increases metabolic rate, fat burning</li>
    </ol>

    <p><strong>Current triple agonist: Retatrutide</strong> (Eli Lilly, Phase 3 trials)</p>

    <h2>Single vs Dual vs Triple Agonists</h2>

    <h3>Single Agonists (Semaglutide)</h3>
    <ul>
      <li>Target: GLP-1 only</li>
      <li>Weight loss: 10-15%</li>
      <li>Proven, safe, widely used</li>
    </ul>

    <h3>Dual Agonists (Tirzepatide, CagriSema)</h3>
    <ul>
      <li>Target: GLP-1 + GIP (or GLP-1 + Amylin)</li>
      <li>Weight loss: 15-22.5%</li>
      <li>Better than single agonists</li>
    </ul>

    <h3>Triple Agonists (Retatrutide)</h3>
    <ul>
      <li>Target: GLP-1 + GIP + Glucagon</li>
      <li>Weight loss: 24-28.7%</li>
      <li><strong>Most effective to date</strong></li>
    </ul>

    <h2>Why Triple Agonists Work Better</h2>
    <p><strong>The glucagon addition is key:</strong></p>
    <ul>
      <li>Boosts resting metabolic rate (burn more calories at rest)</li>
      <li>Enhances fat oxidation (body burns stored fat more efficiently)</li>
      <li>Prevents metabolic slowdown common with weight loss</li>
      <li>Synergistic effects with GLP-1 and GIP</li>
    </ul>

    <h2>Are Triple Agonists Safe?</h2>
    <p><strong>Clinical trial data shows:</strong> Retatrutide's side effects are similar to dual agonists (tirzepatide). Adding glucagon didn't significantly worsen GI side effects.</p>

    <p><strong>Caveat:</strong> Triple agonists have less real-world safety data than semaglutide (5+ years) or tirzepatide (2+ years).</p>

    <h2>When Will Triple Agonists Be Available?</h2>
    <ul>
      <li><strong>Retatrutide:</strong> 2027-2028 FDA approval expected</li>
      <li><strong>Other triple agonists:</strong> Various companies developing (2028-2030+)</li>
    </ul>

    <h2>Should You Wait for Triple Agonists?</h2>
    <p><strong>For most people: No.</strong> Dual agonist tirzepatide (15-22.5% weight loss) is available NOW and delivers excellent results. Start losing weight today rather than waiting 1-2 years.</p>

    <p><strong>You can always switch:</strong> Start tirzepatide now, lose 30-50 pounds, then switch to retatrutide when it's approved if you want even better results.</p>

    <MedicalDisclaimer />
  </div>
</BaseLayout>
